
After trouncing the broader markets between 2004 and 2015, Gilead Sciences (GILD) has underperformed significantly in the last eight years. By the numbers, Gilead Sciences stock rose 1,550% between February 2004 and August 2015, when it traded near all-time highs. Today, the healthcare giant is down about 41% from record levels, valuing the company at a market cap of $89 billion.
